Technical report: a high-dose-rate interstitial brachytherapy boost for residual sinonasal undifferentiated carcinoma. 2022

Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Sinonasal undifferentiated carcinoma (SNUC) is a highly aggressive and uncommon neoplasm that arises from the mucosa of the nasal cavity or paranasal sinuses. The multidisciplinary approach that includes surgery, radiation therapy (RT), and chemotherapy has been proven to improve survival rates. However, there is no established evidence for the efficacy of further (boost) irradiation following definitive RT in SNUC patients with residual primary tumor. We describe a successful case of a patient with SNUC who had an uncontrolled primary tumor following induction chemotherapy and radical concurrent chemoradiotherapy (CCRT) and underwent a high-dose-rate interstitial brachytherapy (HDR-ISBT) boost. A 75-year-old Japanese woman with unresectable locally advanced SNUC (LA-SNUC) received induction chemotherapy followed by radical CCRT. However, because the residual primary tumor was evident after planned external beam RT, she underwent an HDR-ISBT boost, and the tumor decreased significantly. A complete response (the Response Evaluation Criteria in Solid Tumors, ver. 1.1) was achieved 2 months after brachytherapy, and the patient has been disease-free for 2 years following treatment initiation. In conclusion, an HDR-ISBT boost can be a safe and effective treatment option in patients with residual and inoperable LA-SNUC in the maxillary sinus after initial RT.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 1998, Clinical oncology (Royal College of Radiologists (Great Britain)),
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2013, Brachytherapy,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2017, Brachytherapy,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2019, Brachytherapy,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
November 2014, Radiation oncology (London, England),
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2023, Japanese journal of clinical oncology,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
June 2020, Journal of contemporary brachytherapy,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2009, Brachytherapy,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
September 1999, International journal of radiation oncology, biology, physics,
Yusaku Miyata, and Naoya Murakami, and Yoshitaka Honma, and Taisuke Mori, and Seiichi Yoshimoto, and Tairo Kashihara, and Mihiro Takemori, and Yuko Nakayama, and Jun Itami, and Etsuyo Ogo, and Hiroshi Igaki
January 2013, Tumori,
Copied contents to your clipboard!